ArticleDiscover oncology2025
Deciphering the role of cathepsins in digestive system cancers: a Mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digestive system cancers (DSCs) present a global health challenge. This study aimed to investigate the causal relationships between cathepsins and DSCs using Mendelian Randomization (MR) analysis. Single Nucleotide Polymorphisms (SNPs) associated with nine cathepsin types (cathepsins B, E, F, G, H, O, S, L2, Z) were obtained from the INTERVAL study (3301 individuals). Genetic association data for DSCs were obtained from a large-scale GWAS conducted by Sakaue et al. (Nat Genet 53: 1415-1424, 2021), while SNPs associated with cathepsin expression were sourced from the INTERVAL study. (esophageal cancer: 998 cases, 475,308 controls; gastric cancer: 1,029 cases, 475,087 controls; colorectal cancer: 6,581 cases, 463,421 controls; hepatic cancer: 379 cases, 475,259 controls; pancreatic cancer: 1,196 cases, 475,049 controls). Inverse variance weighted (IVW), MR-Egger, and weighted median methods were adopted to conduct univariable MR (UVMR), reverse MR, and multivariable MR (MVMR) analyses to estimate causality. The UVMR analyses discovered that elevated SNP-predicted cathepsin S expression were significantly associated with increased colorectal cancer risk(IVW: p = 0.0162, odds ratio (OR) = 1.0513, 95% confidence interval (CI) = 1.0093-1.0951), whereas cathepsin H exhibited a protective role against pancreatic cancer(IVW: p = 0.0410, OR = 0.9131, 95% CI = 0.8369-0.9963). These findings were corroborated by the MVMR analyses (cathepsin S: IVW: p = 0.0040, OR = 1.0725, 95%CI = 1.0233-1.1252; cathepsin H: IVW: p = 0.0160, OR = 0.8851, 95%CI = 0.8025-0.9773). No reverse causality was found. Our findings suggested the potential causalities of cathepsins S on colorectal cancer and cathepsin H on pancreatic cancer, indicating their potential as biomarkers and therapeutic targets in DSCs. Further research is necessary to integrate these genetic associations into clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.